title: Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction.
abstract: Seventy-seven patients with diagnosis of schizophrenia (62) or schizoaffective disorder (15) were studied 2-20 years since onset of illness, when in a stable condition. The investigation included clinical assessment, measurement of plasma concentrations of neuroleptics and prolactin, computed tomography brain scan, neuropsychological and neurological examination. Outcome of illness was classified according to the presence of chronic psychiatric symptoms and social impairment, and response to neuroleptics according to the effect of treatment in the most recent psychotic episode. Neither outcome nor response to neuroleptics was related to duration of illness. The groups with good and poor outcome differed in premorbid adjustment, age at onset and symptoms of the initial episode, but not in drug bio-availability or prolactin response. Large cerebral ventricles and cognitive impairment, but not neurological 'soft' signs, were associated with unfavourable outcome. The three measures of organicity were not inter-related. No clinical differences were found between chronic patients with and without signs of organic dysfunction. The findings suggest that schizophrenia with good and unfavourable outcome may be separate sub-types. However, the role of organic factors in the latter group remains unclear.
authors.forename: T
authors.initials: T
authors.lastname: Kolakowska
authors.forename: A O
authors.initials: AO
authors.lastname: Williams
authors.forename: M
authors.initials: M
authors.lastname: Ardern
authors.forename: M A
authors.initials: MA
authors.lastname: Reveley
authors.forename: K
authors.initials: K
authors.lastname: Jambor
authors.forename: M G
authors.initials: MG
authors.lastname: Gelder
authors.forename: B M
authors.initials: BM
authors.lastname: Mandelbrote
mesh_terms: D000328:Adult; D000978:Antiparkinson Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001921:Brain / Q000000981:diagnostic imaging; D002746:Chlorpromazine / Q000627:therapeutic use; D003072:Cognition Disorders / Q000150:complications; D005260:Female; D005475:Flupenthixol / Q000097:blood; D005476:Fluphenazine / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011388:Prolactin / Q000097:blood; D011618:Psychotic Disorders / Q000175:diagnosis; D012559:Schizophrenia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D014057:Tomography, X-Ray Computed
chemical_list: D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D011388:Prolactin; D005475:Flupenthixol; D005476:Fluphenazine; D002746:Chlorpromazine